📰 Thomask Equels News
Page 5 - Thomask Equels News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Thomask Equels. Real-time updates on events, politics, business and more.
May 9, 2023
OCALA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the...
April 12, 2023
Company's SAB is comprised of well-established leaders with expertise across biomedical research, academia, and pharmaceutical industry OCALA, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech
April 12, 2023
Company’s SAB is comprised of well-established leaders with expertise across biomedical research, academia, and pharmaceutical industry OCALA, Fla., April 12, 2023 -- AIM ImmunoTech Inc. ,... | April 12, 2023
March 27, 2023
OCALA, Fla., March 27, 2023 -- AIM ImmunoTech Inc. , an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and... | March 27, 2023
March 25, 2023
AIM ImmunoTech Inc. (NYSE:AIM – Get Rating) traded down 4.2% on Friday . The company traded as low as $0.41 and last traded at $0.42. 93,307 shares were traded during trading, a decline of 64% from the average session volume of 256,005 shares. The stock had previously closed at $0.44. AIM ImmunoTech Stock Down 4.2 […]
March 16, 2023
Growing body of data supports Ampligen's potential as both a prophylactic and an early-onset therapy against human Ebola virus disease outbreaksOCALA, Fla., March 16, 2023th International Conference on
March 14, 2023
/PRNewswire/ -- USA News Group - Optimism is on the rise as the American Cancer Society is reporting that the five-year survival rate for those diagnosed with...
March 14, 2023
FN Media Group Presents USA News Group News Commentary VANCOUVER, BC, March 14, 2023 /PRNewswire/ -- USA News Group - Optimism is on the rise as the American Cancer Society is reporting
February 28, 2023
Ongoing efforts to open additional clinical sites for recruitment at premier cancer centers across the U.S. and Europe are in progress to facilitate...
January 17, 2023
17.01.2023 - Research collaboration will evaluate the potential of AIM’s Ampligen (rintatolimod) in combination with AstraZeneca’s Imfinzi (durvalumab) for the treatment of pancreatic cancerOCALA, Fla., Jan. 17, 2023 (GLOBE NEWSWIRE) - AIM ImmunoTech Inc. ... Seite 1